Dermata Therapeutics, Inc. (NASDAQ:DRMA) Short Interest Update

Dermata Therapeutics, Inc. (NASDAQ:DRMA) was the recipient of a significant increase in short interest in the month of January. As of January 31st, there was short interest totalling 294,200 shares, an increase of 112.9% from the January 15th total of 138,200 shares. Currently, 47.5% of the shares of the stock are sold short. Based on an average daily volume of 460,200 shares, the days-to-cover ratio is currently 0.6 days.

Dermata Therapeutics Stock Performance

Shares of DRMA stock opened at $1.19 on Friday. The company has a market capitalization of $2.43 million, a PE ratio of -0.07 and a beta of 0.67. Dermata Therapeutics has a 52-week low of $1.00 and a 52-week high of $7.62. The business’s fifty day moving average is $1.25 and its 200 day moving average is $1.48.

About Dermata Therapeutics

Dermata Therapeutics, Inc, a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea.